Takeda Pharmaceutical (NYSE:TAK) Releases FY 2024 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 3.330-3.330 for the period. The company issued revenue guidance of $30.1 billion-$30.1 billion.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock traded up $0.34 during trading on Thursday, hitting $13.65. 1,077,594 shares of the company were exchanged, compared to its average volume of 1,952,328. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. Takeda Pharmaceutical has a fifty-two week low of $12.57 and a fifty-two week high of $15.08. The stock has a market capitalization of $43.42 billion, a price-to-earnings ratio of 23.54, a P/E/G ratio of 0.24 and a beta of 0.51. The firm has a 50 day moving average price of $13.30 and a 200 day moving average price of $13.89.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 10.00% and a net margin of 6.49%. On average, equities analysts expect that Takeda Pharmaceutical will post 1.55 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.